NASDAQ:ATHA Athira Pharma Q2 2025 Earnings Report $3.87 +0.04 (+1.04%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.83 -0.04 (-1.03%) As of 09/19/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Athira Pharma EPS ResultsActual EPS-$1.80Consensus EPS -$1.80Beat/MissMet ExpectationsOne Year Ago EPSN/AAthira Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAthira Pharma Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time7:00AM ETUpcoming EarningsAthira Pharma's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Athira Pharma Earnings HeadlinesAthira Pharma price target lowered to $4 from $5 at MizuhoSeptember 19 at 5:42 PM | msn.comAthira Pharma trading halted, news pendingSeptember 18 at 2:05 AM | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.September 20 at 2:00 AM | American Alternative (Ad)Athira Pharma announces a 10-for-1 reverse stock splitSeptember 12, 2025 | msn.comAthira Pharma, Inc.: Athira Pharma Announces Reverse Stock SplitSeptember 11, 2025 | finanznachrichten.deAthira Pharma, Inc. Announces 10-for-1 Reverse Stock Split Effective September 17, 2025September 11, 2025 | quiverquant.comQSee More Athira Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email. Email Address About Athira PharmaAthira Pharma (NASDAQ:ATHA) is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS). The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system. Fosgonimeton has advanced through Phase 1 and Phase 2 clinical trials, where it has been evaluated for safety, tolerability and preliminary efficacy in patients with mild to moderate Alzheimer’s disease and other forms of cognitive impairment. In addition to ATH‐1017, the company is exploring follow‐on small‐molecule candidates designed to target related pathways and broaden the potential therapeutic impact across multiple neurodegenerative indications. Athira Pharma went public in 2019 and is traded on the Nasdaq under the symbol ATHA. The company conducts clinical studies in the United States and Europe in collaboration with academic research centers and contract research organizations. Leadership has included key figures from both the biotech and neuroscience research communities, with a management team experienced in drug development, clinical operations and regulatory affairs. Athira continues to engage with strategic partners to support its mission of bringing novel, disease‐modifying treatments to patients suffering from progressive neurological disorders.View Athira Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Berkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into Believers Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
